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ABSTRACT
R
earrangements of our genome can be responsible for
inherited as well as sporadic traits. The analyses of
chromosome breakpoints in the proximal short arm
of Chromosome 17 (17p) reveal nonallelic homologous
recombination (NAHR) as a major mechanism for recurrent
rearrangements whereas nonhomologous end-joining (NHEJ)
can be responsible for many of the nonrecurrent
rearrangements. Genome architectural features consisting of
low-copy repeats (LCRs), or segmental duplications, can
stimulate and mediate NAHR, and there are hotspots for the
crossovers within the LCRs. Rearrangements introduce
variation into our genome for selection to act upon and as
such serve an evolutionary function analogous to base pair
changes. Genomic rearrangements may cause Mendelian
diseases, produce complex traits such as behaviors, or
represent benign polymorphic changes. The mechanisms by
which rearrangements convey phenotypes are diverse and
include gene dosage, gene interruption, generation of a
fusion gene, position effects, unmasking of recessive coding
region mutations (single nucleotide polymorphisms, SNPs, in
coding DNA) or other functional SNPs, and perhaps by
effects on transvection.
Introduction
Whereas Watson–Crick DNA base pair changes have long
been recognized as a mechanism for mutation,
rearrangements of the human genome including deletions,
duplications, and inversions have been appreciated only
more recently as a signiﬁcant source for genetic variation.
Deletion and duplication mutations can vary in size from
thousands to hundreds of thousands of base pairs in length
and may require specialized technologies to visualize.
Structural features, or the architecture, of the human genome
can result in region-speciﬁc susceptibility to rearrangements
and thus genomic instability. The molecular mechanisms by
which rearrangement mutations of the human genome occur,
and how such rearrangements convey phenotypes, are only
beginning to be unraveled.
During the last decade it has become apparent that the
molecular genetic mechanisms for many disease traits consist
of genomic rearrangements rather than point mutations of
single genes. Such conditions, in which the clinical phenotype
is a consequence of abnormal dosage or dysregulation of one
or more genes resulting from rearrangement of the genome,
have been referred to as genomic disorders [1–4]. DNA
rearrangements occur by both homologous and
nonhomologous recombination mechanisms; however,
homologous recombination (HR) appears to be the
predominant pathway underlying recurrent rearrangements
of our genome. Regardless of mechanism, structural features
of the genome can predispose a particular region to
rearrangement. Determining the architectural features that
result in the instability of the genomic regions has profound
consequences for clinical genetics as new technologies enable
high-resolution analysis of the human genome. This review
will focus on the information culled from, and molecular
mechanisms elucidated by, breakpoint analyses of disease-
associated rearrangements involving proximal 17p. Although
the focus is 17p, such mechanisms appear to be generally
applicable to all regions of the human genome. We also
describe the many mechanisms by which rearrangements can
convey phenotypes and discuss rearrangements as the basis
for introducing variation in our genome.
Proximal 17p Dosage Changes Convey
Phenotypes—An Assay for Rearrangements
Charcot-Marie-Tooth disease type 1A (CMT1A) and
hereditary neuropathy with liability to pressure palsies
(HNPP) are dysmyelinating peripheral neuropathies that
result from an altered dosage of PMP22, which encodes
peripheral myelin protein. CMT1A results from heterozygous
duplication of a 1.4-Mb segment that includes the PMP22
gene, whereas HNPP results from a heterozygous deletion of
the same genomic interval. The rearrangements cause altered
dosage of PMP22 that subsequently results in neuropathy;
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haploinsufﬁciency) leads to HNPP. Experimental evidence in
support of the PMP22 dosage hypothesis is substantive
(reviewed in [5,6]). Sufﬁce it to say that rare nonduplication
CMT1A patients have been identiﬁed with heterozygous
apparent gain-of-function PMP22 point mutations, and rare
nondeletion HNPP patients have loss-of-function PMP22
mutations (nonsense or frameshift alleles) consistent with
haploinsufﬁciency [5]. Animal models that overexpress
PMP22 recapitulate the CMT1A phenotype, and the
neuropathy can be clinically, electrophysiologically, and
neuropathologically corrected by abrogation of the
overexpression using epigenetic manipulation of PMP22 gene
expression [7,8].
Smith-Magenis syndrome (SMS) is a multiple congenital
anomaly/mental retardation disorder usually associated with
a cytogenetically visible heterozygous deletion of sub-band
17p11.2, i.e., del(17)(p11.2p11.2) (reviewed in [9,10]). Rare
patients without deletion have been identiﬁed, and some
were found to have heterozygous point mutations in the
retinoic acid inducible 1 (RAI1) gene [11–13]. As would be
anticipated, most of these are frameshift or nonsense
mutations consistent with a haploinsufﬁciency mechanism.
Chromosome-engineered mouse models that delete one copy
of the mouse Chromosome 11 region syntenic to human
17p11.2 (i.e., Df(11)17 and other derivative deﬁciencies) [14–
16], as well as targeted disruption of Rai1 [17], recapitulate
much of the SMS phenotype. Animal models that are
compound heterozygotes for deletion and duplication
(Df(11)17/Dp(11)17) have a normal phenotype; this ‘‘rescue’’ is
consistent with a dosage mechanism for the phenotypes
DOI: 10.1371/journal.pgen.0010049.g001
Figure 1. Recurrent Rearrangements in Proximal 17p
The horizontal line represents proximal 17p with the telomere (TEL) to
the left, the centromere (circle) to the right, and LCRs demarcated. The
genomic regions duplicated in CMT1A (green horizontal rectangle) and
deleted in HNPP (red horizontal rectangle) are shown above, and the
recurrent deletions associated with SMS and duplication associated with
dup(17)(p11.2p11.2) are shown below. The position of the
isochromosome 17q breakpoint cluster region within a large cruciform
structure (consisting of five subunits of ;40–50 kb each) is also shown.
DOI: 10.1371/journal.pgen.0010049.g002
Figure 2. Nonrecurrent Rearrangements in Proximal 17p
Proximal 17p with its complex genome architecture and multiple LCRs. The centromere (cen) is to the right, telomere (tel) to the left. Filled, hatch-
marked, and color-coded rectangles depict LCR regions of greater than 97% sequence identity, with horizontal arrows depicting orientation. The
locations of the RAI1 gene and isochromosome 17q breakpoint cluster regions are demarcated. Above is shown the region deleted in SMS patients with
uncommon nonrecurrent deletions—the breakpoints are denoted by arrowheads. Below are shown the regions contained in the supernumerary
marker chromosomes (SMCs). Also, below are shown the 17p11.2 breakpoints of the translocations.
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[14]. A syndrome associated with heterozygous duplication of
the genomic interval deleted in SMS, dup(17)(p11.2p11.2), has
been described [18]. The dup(17)(p11.2p11.2) phenotype
likely results from a dosage-sensitive gene in the human
Chromosome 17p11.2 region. This dosage-sensitive gene is
probably RAI1 since Dp(11)17/Rai1
 animals, who have a
normal Rai1 gene copy number but three copies for all the
other genes in the rearranged intervals, have a normal
phenotype (i.e., the knockout allele appears to rescue the
duplication phenotypes; unpublished data), although this
hypothesis awaits formal veriﬁcation.
Thus, alterations of the copy number of either PMP22 or
RAI1 convey a clinical phenotype that usually elicits a visit to
a physician. Therefore, rearrangements involving these genes
can be readily ascertained.
Recurrent Rearrangement Breakpoints Map to LCRs
The CMT1A duplication [19] and HNPP deletion [20] are
transmitted through the germ line and cosegregate with their
respective neuropathy phenotypes as an autosomal dominant
trait. However, both de novo duplication and deletion can
occur in association with sporadic disease. The vast majority
of unrelated patients from families segregating CMT1A, as
well as sporadic cases, have the same size duplication. This
common duplication rearrangement has recurrent
breakpoints that map to LCRs called CMT1A-REPs [21]
(Figure 1). Similarly, HNPP patients have a common deletion
rearrangement with recurrent (i.e., clustered) breakpoints
that map to CMT1A-REPs. It has been shown that the CMT1A
duplication and HNPP deletion represent alternative
products of a NAHR utilizing CMT1A-REPs as recombination
substrates [21,22].
Detection of the CMT1A duplication or HNPP deletion has
turned out to be a useful molecular diagnostic test for the
evaluationofpatientswithneuropathy.Thousandsofteststhat
detect a junction fragment (i.e., a novel band that reﬂects the
rearrangement and can be identiﬁed at the breakpoint
junction) speciﬁc to either the duplication or deletion have
been performed since the early 1990s. Essentially all CMT1A
and HNPP patients with a rearrangement mutation, with the
exception of three reported CMT1A patients harboring a
smallerduplicationandacoupleofHNPPpatientswithsmaller
deletions (reviewed in [5]), have had the common recurrent
rearrangement. Thus, in greater than 99% of the families with
rearrangementsthenewmutationappearstohaveoccurredby
NAHR.However,itisimportanttonotethatthemoleculartest
thatassaysforaspeciﬁcjunctionfragmentmaynotdetectsome
smaller or larger sized duplications.
In contrast to CMT1A and HNPP, which usually segregate
as dominant traits, SMS is essentially always a sporadic
disease associated with a de novo del(17)(p11.2p11.2) [23–26].
In the majority of SMS patients with cytogenetically visible
deletions, the breakpoints are recurrent and cluster in LCRs
termed SMS-REPs [25–28] (Figure 1). The common recurrent
SMS deletion occurs by NAHR utilizing SMS-REPs as the
recombination substrates [29,30]. A common recurrent
rearrangement occurs in 70%–80% of deletion patients with
SMS [31].
Approximately 20%–30% of SMS patients do not harbor
the common deletion, but instead have uncommon sized
deletions. Interestingly, some of the uncommon deletion
rearrangements [32,33], representing about 4% of the total
SMS deletions studied, were also found to have recurrent
breakpoints. As anticipated, these recurrent breakpoints
mapped to yet another LCR family—LCR17ps [34] (Figure 1).
These uncommon recurrent SMS rearrangements also occur
by NAHR, utilizing LCR17p ﬂanking repeats as
recombination substrates. Whereas the predicted reciprocal
duplication of the common SMS deletion mediated by SMS-
REP has been identiﬁed [18], the predicted reciprocal
duplication for this uncommon recurrent deletion remains to
be found.
Recombination Hotspots Associated with Strand
Exchanges
Theoretically, HR can occur whenever there is a shared
stretch of homology providing substrates. There does appear
to be a minimal stretch of identity, referred to as a minimal
efﬁcient processing segment (MEPS), required among
substrates to enable HR to occur. The MEPSs that enable HR
to occur in cultured mouse cells have been determined to be
between 132 and 232 bp of perfect shared sequence identity
[35,36]. The MEPS requirements for HR in human meiosis
DOI: 10.1371/journal.pgen.0010049.g003
Figure 3. Molecular Mechanisms for Genomic Disorders
Six models are depicted and include (A) gene dosage, where there is a
dosage sensitive gene within the rearrangement; (B) gene interruption,
wherein the rearrangement breakpoint interrupts a gene; (C) gene fusion
whereby a fusion gene is created at the breakpoint that either fuses
coding sequences or a novel regulatory sequence to the gene; (D)
position effect, in which the rearrangement has effects on expression/
regulation of a gene near the breakpoint, potentially by removing or
altering a regulatory sequence; (E) unmasking recessive allele, where a
deletion results in hemizygous expression of a recessive mutation or
further uncovers/exacerbates effects of a functional polymorphism; and
(F) by potentially interrupting effects of transvection, where the deletion
of a gene and its surrounding regulatory sequences affects the
communication between alleles. In each model, both chromosome
homologs are depicted as horizontal lines. The rearranged genomic
interval is enclosed by brackets—dashed lines indicate genomic regions
either deleted or duplicated, an absent line indicates deletion with
phenotypic effects from the remaining allele unmasked because of the
rearrangement, and a dotted line represents deletion but where
phenotypic effects result from the absence of interactions between
alleles (i.e., transvection effects). Gene is depicted by filled horizontal
rectangle, while regulatory region is shown as a hatch-marked rectangle.
Asterisks denote point mutations.
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thousand base pairs in length and more than 98% identity, a
strand exchange could occur potentially wherever there are
the required MEPSs. However, experimental observations
from multiple NAHR studies document positional
preferences, or recombination hotspots, wherein the
crossovers preferentially occur [37]. This was initially
observed within the 24-kb CMT1A-REP [37,38], but found
also in the ;200-kb SMS-REP [30] and ;125-kb LCR17p [34].
Interestingly, hotspots for strand exchange have been
documented also for allelic HR (AHR) across the human
genome [39–41]. Common features shared among NAHR and
AHR hotspots include the following: clustering within small
(,1 kb) genomic regions, coincidence with apparent gene
conversion events, and no obvious sequence similarities with
one another [37]. This last feature distinguishes mammalian
HR from HR in prokaryotes, wherein a cis-acting
recombinogenic heptameric sequence motif (v or chi [42])
stimulates recombination. Whether NAHR and AHR hotspots
are coincident in the human genome remains to be
determined. It is also not clear if recombination hotspots
reﬂect cis-acting sequence motifs, positional preference of
trans-acting factors, or unusual non-B DNA structures [43], or
rather just denote genomic regions more susceptible to DNA
double-strand breaks.
NAHR—A General Mechanism for Generating
Rearrangements of Our Genome
With the description of the reciprocity for NAHR, e.g., the
CMT1A duplication/HNPP deletion and the SMS deletion/
dup(17)(p11.2p11.2), it is anticipated that all deletion
syndromes in which the rearrangement breakpoints cluster in
ﬂanking LCRs will likely have reciprocal duplication
syndromes. One challenge is to identify such reciprocal
duplications and document their role in causing a speciﬁc
phenotype. In addition to deletion/duplication
rearrangements mediated by NAHR using directly oriented
LCRs as substrates, NAHR can also produce inversion
rearrangements if inverted LCRs are utilized as the
recombination substrates. Such inversion rearrangements
can disrupt genes and cause disease traits [44], predispose
DNA to deleterious genomic rearrangements [45–48], or be
responsible for haplotype blocks essentially creating a
balancer chromosome that suppresses recombination [49].
Somatic NAHR between nonsister chromatids can result in
the formation of an isochromosome [50].
Nonrecurrent Rearrangements
The breakpoints of ;20%–30% of deletions in patients
with SMS do not map to the proximal and distal copies of
SMS-REP as in the common recurrent deletions [32,33]
(Figure 2). Such deletion patients are readily ascertained
because their phenotype also results from RAI1
haploinsufﬁciency. Interestingly, the breakpoints of these
nonrecurrent rearrangements often map to LCRs [33].
However, the observation that the two breakpoints could be
in different LCRs is inconsistent with homology mediating
these events. Thus, LCRs may stimulate but do not appear to
mediate nonrecurrent rearrangements. Sequencing the
breakpoint junctions to examine the products of
recombination for four such nonrecurrent rearrangements
revealed NHEJ as the mechanism in two whereas the other
two represented Alu–Alu recombinations between closely
related (i.e., sharing a high degree of sequence identity) Alu
sequences [51].
LCRs have also been identiﬁed at the breakpoints of three
of four small marker Chromosomes 17 [52–54] and in some
apparently balanced translocations with breakpoints in 17p
[33] (Figure 2), but the DNA sequence at these breakpoints
has not been determined so the exact recombination
mechanism remains to be elucidated. Interestingly,
breakpoints for small marker chromosomes and
translocations also often map to (peri)centromeric
sequences.
NHEJ—An Alternative Pathway
It is clear that not all rearrangements in our genome are
mediated by HR. As documented above, evidence for NHEJ
has been found by examining breakpoints for some deletions
causing SMS. However, this represents less than 20%–25% of
SMS deletion cases. Nevertheless, it remains to be determined
to what extent NHEJ is a mechanism for genome
rearrangement. NHEJ may potentially have a more
prominent role in nonrecurrent rearrangements [55–57].
Somatic Rearrangements
The molecular investigations of somatic rearrangements
pose additional challenges to those encountered in the study
of constitutional rearrangements. In constitutional
rearrangements the tissue used for a source of DNA is usually
uniform in its genetic constitution. In a somatic
rearrangement event, the tissue source for isolating the DNA
to study by molecular methods may represent a mosaic
mixture of cells that contain the rearrangement with cells
that have a normal, or wild-type, genome. This may be further
complicated in a tumor, wherein multiple different and serial
rearrangement events can occur. Nevertheless, for one
somatic 17p rearrangement, molecular analyses revealed
complex genomic architecture at clustered breakpoints and
led to a model that explains the molecular mechanism for its
formation [50].
Isochromosome 17q is a common recurrent genomic
rearrangement observed in human neoplasms and was shown
earlier to be isodicentric with clustered breakpoints [58].
Subsequently, a complex genomic architecture characterized
by large (38–49 kb) cruciform LCRs was identiﬁed at the
breakpoint cluster region [50]. DNA breaks generated in the
hairpin/cruciform structures were postulated to trigger the
double-strand-break repair pathway. A subsequent NAHR
event between repeats of opposite orientation on sister
chromatids (i.e., sister chromatid exchange) can result in the
formation of an isodicentric Chromosome 17 and an acentric
fragment [50]. The recognition of breakpoint clustering and
determination of the mechanism for isochromosome
formation enabled the development of a FISH-based test to
assay the rearrangement event [59].
Molecular Mechanisms by Which Constitutional
Rearrangements Convey Phenotypes
Deletion and duplication rearrangements can cause a
phenotype by several molecular mechanisms (Figure 3A–3D),
PLoS Genetics | www.plosgenetics.org December 2005 | Volume 1 | Issue 6 | e49 0630including altering the copy number of a gene (or genes)
sensitive to a dosage effect, as exempliﬁed by PMP22 and
RAI1. The breakpoint of the rearrangement may interrupt a
gene and cause a loss-of-function by inactivating a gene.
Alternatively, a fusion gene can form at the breakpoint
generating a gain-of-function mutation; a mechanism
prominent amongst cancers associated with speciﬁc
chromosomal translocations. Rearrangements can also
manifest through a position effect [60]. Such position effects
have been documented for apparently balanced
translocations that even exert their inﬂuence when the
breakpoints map as far as ;1 Mb away either upstream or
downstream from the culprit gene [61]. Position effects have
been observed also with deletion [60] and duplication [62]
rearrangements that occur outside the intact gene.
Other molecular mechanisms by which rearrangements of
the genome may convey or alter a disease phenotype result
from how the rearrangement on one chromosome affects or
is affected by the allele on the other chromosome at that
locus (Figure 3E and 3F). These include the unmasking of
either recessive mutations (reviewed in [63]) or functional
polymorphisms [64] of the remaining allele when a deletion
occurs, and potential transvection (communication between
alleles on homologous chromosomes) [16,17] effects via
deletion of regulatory elements required for communication
between alleles.
Copy-Number Variations
Recent excitement has been generated by the observation
that individuals may vary for large segments of their genome,
with evidence for both decreased and increased copy number
[65–67]. This revelation has been enabled by array
technologies that allow high-resolution screening of the
entire human genome simultaneously. It is not clear to what
extent such genomic changes are responsible for Mendelian
or complex disease traits and common traits (including
behavioral traits), or represent only benign polymorphic
variation. In fact, it is impossible to assay individuals with
such genomic changes for all potential phenotypes that can
occur. Furthermore, some phenotypes caused by genomic
rearrangements (e.g., HNPP) may not present until late
adulthood—if at all [5,6]. This age-dependent penetrance
confounds the interpretation of genomic copy-number
changes. Copy-number changes have been associated with
phenotypes that are often difﬁcult to ascertain such as
susceptibility to HIV infection [68].
Copy-number variations (CNVs), alternatively referred to as
large-segment copy-number variations (LCVs) [65] or copy-
number polymorphisms (CNPs) [66], of genomic regions have
been reported to occur near segmental duplications or LCRs
[65,66,69]. However, the involvement of segmental
duplications, perhaps by an LCR/NAHR mechanism, is yet to
be determined. Segmental duplications account for some 5%–
10% of the human genome [70–72], and CNVs may be
coincident with LCRs by chance. Nevertheless, it is clear that
LCR/NAHR-generated rearrangements occur throughout the
genome [1,2], and therefore it is not unreasonable to assume
that such rearrangements or CNVs could be associated with
inherited or sporadic (de novo rearrangement) disease,
susceptibility to disease, complex traits, or common benign
traits, or could represent polymorphic variation with no
apparent phenotypic consequences (Figure 4), depending on
whether or not dosage-sensitive genes are affected by the
rearrangement. In fact, analogous to base pair changes,
rearrangements introduce variations into the genome for
selection to act upon (Figure 5). Perhaps LCR/NAHR is
analogoustothechangesintroducedbyareplicationerrorata
nucleotide base: both are endogenous molecular mechanisms
that introduce variation into our genome. Early comparative
genomics studies among bacterial species revealed substantive
evidence for genome rearrangements and insertion/deletion
events that accompany genome evolution [73,74].
Conclusion
During the previous decade, we have witnessed the
uncovering of recurrent submicroscopic rearrangements as a
DOI: 10.1371/journal.pgen.0010049.g004
Figure 4. Genomic Rearrangements and Phenotypic Traits
Above is shown a gradient/threshold for trait manifestation. Whether or
not a trait is manifested is a function of the dosage sensitivity of the
gene(s) affected by the rearrangement. Below are examples of traits that
can be due to DNA rearrangements. DGS, DiGeorge syndrome; dz,
disease; IP, incontientia pigmenti; MR, mental retardation; PWS/AS,
Prader-Willi syndrome/Angelman syndrome; WBS, Williams-Beuren
syndrome.
DOI: 10.1371/journal.pgen.0010049.g005
Figure 5. CNVs versus Nucleotide Changes
The two major mechanisms by which variation is introduced into our
genome are shown. Such variations can be introduced by both
endogenous and exogenous means. These mutations can cause a
disease trait if they affect gene structure, function, or regulation, as well
as through the alteration of dosage. SNP, single nucleotide
polymorphism.
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genome has allowed detection of genome changes not
observed previously because of technology limitations [4].
The availability of the ‘‘ﬁnished’’ human genome sequence
[75] and genomic microarrays have enabled approaches to
resolve changes in the genome heretofore impossible to
assess, particularly on a global genome scale, i.e.,
simultaneously examining the entire genome rather than
discreet segments [76]. During the past ﬁve decades, since the
elucidation of the chemical basis of heredity by Watson and
Crick, base pair changes have dominated our thinking with
regard to mutation and variation. Rearrangements of our
genome are perhaps introducing mutation and variation to a
greater extent than was recognized previously. &
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